Cargando…

Robust expression of tumor suppressor miRNA’s let-7 and miR-195 detected in plasma of Saudi female breast cancer patients

BACKGROUND: Female breast cancer is frequently diagnosed at a later stage and the leading cause of cancer deaths world-wide. Levels of cell-free circulating microRNAs (miRNAs) can potentially be used as biomarkers to measure disease progression in breast cancer patients in a non-invasive way and are...

Descripción completa

Detalles Bibliográficos
Autores principales: Qattan, Amal, Intabli, Haya, Alkhayal, Wafa, Eltabache, Chafica, Tweigieri, Taher, Amer, Suad Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706292/
https://www.ncbi.nlm.nih.gov/pubmed/29183284
http://dx.doi.org/10.1186/s12885-017-3776-5
_version_ 1783282200144248832
author Qattan, Amal
Intabli, Haya
Alkhayal, Wafa
Eltabache, Chafica
Tweigieri, Taher
Amer, Suad Bin
author_facet Qattan, Amal
Intabli, Haya
Alkhayal, Wafa
Eltabache, Chafica
Tweigieri, Taher
Amer, Suad Bin
author_sort Qattan, Amal
collection PubMed
description BACKGROUND: Female breast cancer is frequently diagnosed at a later stage and the leading cause of cancer deaths world-wide. Levels of cell-free circulating microRNAs (miRNAs) can potentially be used as biomarkers to measure disease progression in breast cancer patients in a non-invasive way and are therefore of high clinical value. METHODS: Using quantitative RT-PCR, circulating miRNAs were measured in blood samples collected from disease-free individuals (n = 34), triple-negative breast tumours (TNBC) (n = 36) and luminal tumours (n = 57). In addition to intergroup comparisons, plasma miRNA expression levels of all groups were analyzed against RNASeq data from cancerous breast tissue via The Cancer Genome Atlas (TCGA). RESULTS: A differential set of 18 miRNAs were identified in the plasma of breast cancer patients and 10 miRNAs were uniquely identified based on ROC analysis. The most striking findings revealed elevated tumor suppressor let-7 miRNA in luminal breast cancer patients, irrespective of subtype, and elevated miR-195 in plasma of TNBC breast cancer patients. In contrast, hsa-miR-195 and let-7 miRNAs were absent from cancerous TCGA tissue and strongly expressed in surrounding non-tumor tissue indicating that cancerous cells may selectively export tumor suppressor hsa-miR-195 and let-7 miRNAs in order to maintain oncogenesis. CONCLUSIONS: While studies have indicated that the restoration of let-7 and miR-195 may be a potential therapy for cancer, these results suggested that tumor cells may selectively export hsa-miR-195 and let-7 miRNAs thereby neutralizing their potential therapeutic effect. However, in order to facilitate earlier detection of breast cancer, blood based screening of hsa-miR-195 and let-7 may be beneficial in a female patient cohort. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-017-3776-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5706292
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57062922017-12-05 Robust expression of tumor suppressor miRNA’s let-7 and miR-195 detected in plasma of Saudi female breast cancer patients Qattan, Amal Intabli, Haya Alkhayal, Wafa Eltabache, Chafica Tweigieri, Taher Amer, Suad Bin BMC Cancer Research Article BACKGROUND: Female breast cancer is frequently diagnosed at a later stage and the leading cause of cancer deaths world-wide. Levels of cell-free circulating microRNAs (miRNAs) can potentially be used as biomarkers to measure disease progression in breast cancer patients in a non-invasive way and are therefore of high clinical value. METHODS: Using quantitative RT-PCR, circulating miRNAs were measured in blood samples collected from disease-free individuals (n = 34), triple-negative breast tumours (TNBC) (n = 36) and luminal tumours (n = 57). In addition to intergroup comparisons, plasma miRNA expression levels of all groups were analyzed against RNASeq data from cancerous breast tissue via The Cancer Genome Atlas (TCGA). RESULTS: A differential set of 18 miRNAs were identified in the plasma of breast cancer patients and 10 miRNAs were uniquely identified based on ROC analysis. The most striking findings revealed elevated tumor suppressor let-7 miRNA in luminal breast cancer patients, irrespective of subtype, and elevated miR-195 in plasma of TNBC breast cancer patients. In contrast, hsa-miR-195 and let-7 miRNAs were absent from cancerous TCGA tissue and strongly expressed in surrounding non-tumor tissue indicating that cancerous cells may selectively export tumor suppressor hsa-miR-195 and let-7 miRNAs in order to maintain oncogenesis. CONCLUSIONS: While studies have indicated that the restoration of let-7 and miR-195 may be a potential therapy for cancer, these results suggested that tumor cells may selectively export hsa-miR-195 and let-7 miRNAs thereby neutralizing their potential therapeutic effect. However, in order to facilitate earlier detection of breast cancer, blood based screening of hsa-miR-195 and let-7 may be beneficial in a female patient cohort. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-017-3776-5) contains supplementary material, which is available to authorized users. BioMed Central 2017-11-28 /pmc/articles/PMC5706292/ /pubmed/29183284 http://dx.doi.org/10.1186/s12885-017-3776-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Qattan, Amal
Intabli, Haya
Alkhayal, Wafa
Eltabache, Chafica
Tweigieri, Taher
Amer, Suad Bin
Robust expression of tumor suppressor miRNA’s let-7 and miR-195 detected in plasma of Saudi female breast cancer patients
title Robust expression of tumor suppressor miRNA’s let-7 and miR-195 detected in plasma of Saudi female breast cancer patients
title_full Robust expression of tumor suppressor miRNA’s let-7 and miR-195 detected in plasma of Saudi female breast cancer patients
title_fullStr Robust expression of tumor suppressor miRNA’s let-7 and miR-195 detected in plasma of Saudi female breast cancer patients
title_full_unstemmed Robust expression of tumor suppressor miRNA’s let-7 and miR-195 detected in plasma of Saudi female breast cancer patients
title_short Robust expression of tumor suppressor miRNA’s let-7 and miR-195 detected in plasma of Saudi female breast cancer patients
title_sort robust expression of tumor suppressor mirna’s let-7 and mir-195 detected in plasma of saudi female breast cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706292/
https://www.ncbi.nlm.nih.gov/pubmed/29183284
http://dx.doi.org/10.1186/s12885-017-3776-5
work_keys_str_mv AT qattanamal robustexpressionoftumorsuppressormirnaslet7andmir195detectedinplasmaofsaudifemalebreastcancerpatients
AT intablihaya robustexpressionoftumorsuppressormirnaslet7andmir195detectedinplasmaofsaudifemalebreastcancerpatients
AT alkhayalwafa robustexpressionoftumorsuppressormirnaslet7andmir195detectedinplasmaofsaudifemalebreastcancerpatients
AT eltabachechafica robustexpressionoftumorsuppressormirnaslet7andmir195detectedinplasmaofsaudifemalebreastcancerpatients
AT tweigieritaher robustexpressionoftumorsuppressormirnaslet7andmir195detectedinplasmaofsaudifemalebreastcancerpatients
AT amersuadbin robustexpressionoftumorsuppressormirnaslet7andmir195detectedinplasmaofsaudifemalebreastcancerpatients